Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)

摘要: The spectrum of activity and potency doripenem, a broad-spectrum parenteral carbapenem currently in clinical development, was evaluated using 16 008 bacterial isolates collected as part an international surveillance project during 2003. Using reference broth microdilution methods, doripenem found to be highly active against oxacillin-susceptible Staphylococcus aureus coagulase-negative staphylococci (2705 297 isolates, respectively; MIC90s 0.06 mg/L), with greater than that other antibiotics. Against enterococci (1474 isolates), the exception Enterococcus faecium, displayed modest (MIC50 4). Doripenem among most potent agents tested Streptococcus pneumoniae, viridans group streptococci beta-haemolytic (885, 140 397 isolates; MIC(90)s 0.5, 0.5 0.03 mg/L, respectively). For Enterobacteriaceae (> 6200 four- 32-fold more imipenem wild-type (MIC90s 0.03-0.5 mg/L). for confirmed extended-spectrum beta-lactamase-producing Escherichia coli Klebsiella pneumoniae (121 155 0.12 respectively) were two-fold higher isolates. also Citrobacter spp., Enterobacter spp. Serratia 0.06-0.25 including ceftazidime-resistant meropenem all beta-lactams Pseudomonas aeruginosa (829 MIC50/90s 0.5/8 0.5/16 respectively), whereas Acinetobacter (155 0.5/4